Ovarian cancer is the most common cause of death from gynaecological cancers worldwide. 
Ovarian Tumours
Ovarian cancer is the most common cause of death from gynaecological cancers worldwide. 3 Its aetiology remains unclear, but it is likely multifactorial. Because the ovaries are the best characterised, and physiologically the only undisputed, target of gonadotrophin action in the female, it is natural that tumorigenesis of this organ has been related to their actions. The currently available data are based, on the one hand, on epidemiological association studies of gonadotrophin levels with occurrence of ovarian cancer and, on the other hand, on laboratory studies demonstrating gonadotrophin receptor expression and actions in tumour tissues and cells.
Epidemiological Data on Gonadotrophin Levels and Ovarian Cancer
The 'gonadotrophin theory' of the origin of ovarian cancer has been around for a long time, but because of the variability of evidence it remains hypothetical and controversial. 4, 5 Both elevated endogenous levels of gonadotrophins in conditions such as post-menopause, incessant ovulations and polycystic ovarian syndrome and exposure to exogenous gonadotrophins during infertility treatment have been associated with increased ovarian cancer risk. A major caveat in reaching valid conclusions is that it has been difficult to differentiate effects of the gonadotrophins from those of the basal phenotype of the patients; infertility itself is an independent risk factor for ovarian cancer.
The most recent study on this topic was carried out in Sweden 5 Gonadotrophic Hormones -An Overview of their Involvement in Gonadal and Extragonadal Tumours Curiously, no data are available on gonadotrophin receptor expression in human testicular tumours.
Extragonadal Tumours
Several normal and tumorous extragonadal tissues express gonadotrophin receptors, especially those for LH/hCG. 1, 18 It is therefore natural that direct gonadotrophin actions on these tumours have been proposed, as well as gonadotrophin ablation for their therapy. However, these findings are often confounded by the fact that what appears to be a direct gonadotrophin effect actually occurs through gonadotrophin-stimulated gonadal steroidogenesis.
Uterine Tumours
Several studies have demonstrated the expression of LH/hCG receptors (LHCGR) in normal endometrium, myometrium, uterine vessels and the fallopian tubes. 1 Endometrial cancer expresses LHCGR both at messenger RNA (mRNA) and protein level (see Table 2 ), and one study even demonstrated LH-dependent tumour cell invasion in vitro. 41 Because these tumours also express the hCG subunits, 42 it is possible that there exists at least in a subgroup of them an autocrine hCG/LHCGR circuit that stimulates cell growth. Arcangeli et al. Editor's Choice 
Prostate Tumours
Human benign prostatic hyperplasia and prostate cancer tissues express LHCGR and FSHR (see Table 2 ). 
Adrenal Tumours
Normal adrenocortical tissue expresses LHCGR, and the adrenal gland is the extragonadal tissue with the strongest evidence for functionally meaningful direct gonadotrophin actions. 52 LHCGR expression has been detected in various types of adrenal tumour including adrenocorticotrophic hormone (ACTH)-independent macronodular hyperplasia, aldosterone-producing adrenal adenoma and pregnancyassociated Cushing's syndrome with adrenal adenoma or carcinoma (see Table 2 ). Similar cell-type-dependent effects have been shown with its free β-subunit. [58] [59] [60] Besides gestational trophoblastic disease, in particular hCGβ is produced by some testicular germ cell tumours, cervical and ovarian cancers, bladder, renal, prostate, various gastrointestinal, neuroendocrine, breast, head and neck and haematological cancers.
57,61
The paradox, in particular with breast cancer, is that hCG has been demonstrated to be both protective and promoting for tumour growth.
Only some of these malignancies express LHCGR, 50 colorectal cancer. 63 Another strategy to exploit hCG in cancer therapy is to attach to hCG cytotoxic agents and direct them in this way to LHCGR-epressing tumours.
48,64

Animal Models of Gonadotrophin-dependent Tumorigenesis
Ovarian and Testicular Tumours
The gonadotrophin theory of ovarian tumorigenesis was originally introduced in the 1940s based on an animal model using ovarian autotransplantations into a rat spleen. The transplants developed into tumours in gonadectomised animals exposed to high gonadotrophin levels, but failed to transform when one ovary was left intact or the animal was hypophysectomised, i.e. in the presence of low or normal gonadotrophin levels. 65 Since then, several reports on the development of gonadotrophin-dependent gonadal and extragonadal tumours have been described in genetically susceptible spontaneous 66 or transgenic mouse models. [67] [68] [69] Of note, the gonadotrophindependent ovarian tumours in these models originated mainly from granulosa cells, thus providing models only for a minority (5%) of human ovarian malignancies. Gonadotrophin-dependent testicular tumours developing in the same mouse models usually originate from Sertoli cells 70 Gonadotrophic Hormones -An Overview of their Involvement in Gonadal and Extragonadal Tumours Several rodent models also exist for tumours with OSE origin, and in some of them it has been shown that gonadotrophins do influence tumour growth, [72] [73] [74] [75] thus providing further experimental evidence for the in vitro findings on gonadotrophin-dependent growth of cultured normal and malignant OSE cells (see above). However, with respect to direct tumorigenic effects of gonadotrophins, these studies have to be interpreted with caution because they do not discriminate between direct effects on OSE and indirect effects through stimulation of ovarian steroidogenesis and other potential paracrine factors.
Extragonadal Tumours
The Figure 1) . 69, 81 However, despite the possibility of direct gonadotrophin action due to LHCGR expression in all these tumours, this is apparently not the case, because gonadectomy of the transgenic mice abolishes all extragonadal phenotypes. Therefore, although high gonadotrophin levels are able to induce tumours in extragonadal tissues in rodent models, the effects are invariably secondary to gonadal stimulation and speak against direct tumorigenic effects of these hormones.
Conclusions
A wealth of information exists on gonadotrophin receptor expression in ovarian and extraovarian tumours both in humans and in experimental animal models. There is also in vivo evidence that high gonadotrophin levels may promote both gonadal and extragonadal tumorigenesis. 
